Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
| العنوان: | Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole? |
|---|---|
| المؤلفون: | B Beer, B Sperner-Unterweger, G. Weigel, Ludwig Wildt, Georg Kemmler, Anne Oberguggenberger, Monika Sztankay, Bernhard Holzner, Herbert Oberacher, Martin Daniaux, Michael Hubalek, Verena Meraner, Theresa Czech |
| المصدر: | BMC Cancer BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017) |
| بيانات النشر: | BioMed Central, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Body Mass Index, 0302 clinical medicine, Sex hormone-binding globulin, Breast cancer, Aged, 80 and over, biology, Estradiol, Aromatase Inhibitors, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Postmenopause, Oncology, 030220 oncology & carcinogenesis, Female, Gonadotropin, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Research Article, medicine.medical_specialty, medicine.drug_class, Anastrozole, Breast Neoplasms, lcsh:RC254-282, 03 medical and health sciences, Internal medicine, Nitriles, Genetics, medicine, Humans, Obesity, Aged, Neoplasm Staging, Aromatase inhibitor, business.industry, Estrogens, Triazoles, medicine.disease, 030104 developmental biology, Endocrinology, Estrogen, biology.protein, business, Body mass index, Gonadotropins, Biomarkers, Hormone |
| الوصف: | Background BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since estradiol is inversely correlated with gonadotropins it can be assumed that an impact of BMI is also reflected by gonadotropin plasma concentrations. We aim at investigating the impact of BMI on the hormonal state of breast cancer (BC) patients receiving anastrozole indicated by LH, FSH and SHBG as well as estradiol. Methods We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal, early stage breast cancer patients receiving upfront anastrozole within routine after care. Gonadotropin plasma concentrations were derived from the routine laboratory examination report. A liquid chromatography tandem mass spectrometry method was used for the measurement of anastrozole serum concentrations. BMI was assessed within the routine after-care check-up. Results The overall sample comprised 135 BC patients with a mean age of 65.3 years. BMI was significantly correlated with LH, FSH and SHBG. This association was neither influenced by age nor by anastrozole serum concentrations according to the regression model. Despite aromatase inhibition 12% of patients had detectable estrogen levels in routine quantification. Conclusion Obese women have an altered hormonal situation compared to normally weight women under the same dose of anastrozole. Our study findings are a further indicator for the relevance of BMI in regard of anastrozole metabolism and possible estrogenic activity indicated by gonadotropin plasma level. |
| اللغة: | English |
| تدمد: | 1471-2407 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b95e20d709662d5f9f4a4d69cb4c7b9e http://europepmc.org/articles/PMC5371265 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b95e20d709662d5f9f4a4d69cb4c7b9e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14712407 |
|---|